1. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
by Raajit K. Rampal, John O. Mascarenhas, Heidi E. Kosiorek, Leah Price, Dmitriy Berenzon, Elizabeth Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E. Salama, Kamal Menghrajani, Vesna Najfeld, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Judith D. Goldberg, and Ronald Hoffman
BloodAdv
Volume 2(24):
December 26, 2018
© 2018 by The American Society of Hematology

2. Raajit K. Rampal et al. Blood Adv 2018;2:3572-3580
© 2018 by The American Society of Hematology

3. Myeloproliferative Disease Research Consortium phase 1 study schema.
Raajit K. Rampal et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Duration of treatment by ruxolitinib dose level.
Duration of treatment by ruxolitinib dose level. Corresponding clinical responses are indicated by symbols. End of response is defined as peripheral blood blast count exceeding baseline value. NR, no response.
Raajit K. Rampal et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Maximum change from baseline.
Maximum change from baseline. Peripheral blood blast count per patient (A) and spleen length by palpation in the midclavicular line per patient (B) in patients with palpable splenomegaly at baseline. Dosing cohort designated by color. *Unchanged spleen size.
Raajit K. Rampal et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

6. Overall survival from the time of study enrollment for the cohort as a whole.
Raajit K. Rampal et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology